In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsui & Co. Ltd.

www.mitsui.com

Latest From Mitsui & Co. Ltd.

Will FDA Inspection Observations Fog Speculated Claris Deal?

Claris, the Indian injectables maker, has recently been served five observations by the U.S. FDA related to its manufacturing practices in India. The action coincides with chatter about a deal for the firm’s U.S. businesses which analysts believe may now face obstructions due to the regulatory uncertainty.

BioPharmaceutical India

Will FDA Observations Fog Speculated Claris Deal?

Claris, the Indian injectables maker, has recently been served five observations by the U.S. FDA related to its manufacturing practices in India. The action coincides with a speculated deal for the firm’s U.S. businesses which analysts believe may now face obstructions due to the regulatory uncertainty.

BioPharmaceutical Asia Pacific

Deals Shaping The Medical Industry, May 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Research/Analytical, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April 2015.

BioPharmaceutical Medical Device

Big Deal Brewing At India’s Claris: Sell-off Or JV?

After Agila, which was acquired by Mylan in 2013, Claris, another Indian injectables business, is reported to be on the block. Some in the industry believe if not an outright sell-off, the deal may take the form of a broad-focused global joint venture.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Diversified
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Mitsui Group
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Mitsui & Co. Ltd.
  • Senior Management
  • Tatsuo Yasunaga, Pres. & CEO
  • Contact Info
  • Mitsui & Co. Ltd.
    Phone: (81) 3285-1111
    1-3, Marunouchi 1-chome
    Chiyoda-ku
    Tokyo, 100-8631
    Japan
UsernamePublicRestriction

Register